Dafna Capital Management LLC Kinnate Biopharma Inc. Transaction History

Dafna Capital Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.07 - $2.5 $59,041 - $137,947	-55,179 Reduced 52.46%	50,000 $118,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $3.31 $34,500 - $82,750	25,000 Added 31.18%	105,179 $147,000
Q2 2023 Aug 14, 2023	SELL	$2.33 - $6.84 $1,931 - $5,670	-829 Reduced 1.02%	80,179 $242,000
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $34,600 - $79,800	10,000 Added 14.08%	81,008 $506,000
Q4 2022 Feb 14, 2023	SELL	$5.26 - $12.19 $37,167 - $86,134	-7,066 Reduced 9.05%	71,008 $433,000
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $1.44 Million - $2.31 Million	-146,377 Reduced 65.22%	78,074 $933,000
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $566,909 - $991,900	76,300 Added 51.5%	224,451 $2.83 Million
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $322,325 - $750,147	41,698 Added 39.17%	148,151 $1.67 Million
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $926,796 - $1.29 Million	52,038 Added 95.63%	106,453 $2.45 Million
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $33,285 - $47,325	1,500 Added 2.83%	54,415 $1.27 Million
Q1 2021 May 17, 2021	SELL	$26.99 - $40.0 $410,409 - $608,240	-15,206 Reduced 22.32%	52,915 $1.65 Million
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $2.48 Million - $3.08 Million	68,121 New	68,121 $2.71 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.